Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (3/9/2010)
The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.

Intravesical Taxotere® Effective in Recurrent Superficial Bladder Cancer (7/21/2006)
According to an article recently published in the Journal of Clinical Oncology, administration of the chemotherapy agent Taxotere® (docetaxel) directly into the bladder appears to be an effective treatment option for patients with early bladder cancer that has recurred following standard therapies.

Molecular Technique May Improve Detection of Bladder Cancer Recurrences (5/22/2006)
According to a review published in the journal Urology, a laboratory technique known as fluorescence in situ hybridization (FISH) may allow for earlier and more complete detection of bladder cancer recurrence.

Addition of NMP22® BladderChek® Improves Detection of Recurrent Bladder Cancer (1/18/2006)
According to a recent article published in the Journal of the American Medical Association, the addition of the NMP22® BladderChek® test to cystoscopy improves the detection of recurrent bladder cancer compared to cystoscopy alone.

Aggressive Surgical Treatment of Bladder Cancer Benefits Patients over the Age of 80 (9/9/2004)
Researchers from the University of Michigan have reported that aggressive surgical management of bladder cancer in patients over the age of 80 may improve survival.

Alimta® Provides Responses in Recurrent Bladder Cancer (12/1/2003)
According to results presented at the Chemotherapy Foundation Symposium XXI, Alimta® (pemetrexed) appears to be an active agent in the treatment of recurrent bladder cancer.

Further Evidence Supporting Taxotere® plus Gemzar® in Inoperable Bladder Cancer (11/17/2003)
According to a recent article published in the journal Cancer, the chemotherapy combination Taxotere® (docetaxel) plus Gemzar® (gemcitabine) is effective and well tolerated as treatment for inoperable, advanced bladder cancer. ¹

Immunocyt" Enhances Detection of Bladder Cancer (2/17/2003)
According to a recent article published in The Journal of Urology, the addition of Immunocyt™ to standard testing for bladder cancer appears to greatly enhance accuracy of detection of cancer.

Urine Test May Accurately Detect Bladder Cancer Recurrence (9/25/2002)
According to recent results published in the International Journal of Cancer, a urine test that can detect a genetic mutation (error) referred to as microsatellite instability (MSI) appears to accurately detect the recurrence of bladder cancer.

Mortality from Some Cancer Surgeries Reduced in Large-Volume Hospitals (4/15/2002)
According to a recent article published in The New England Journal of Medicine, death related to surgical procedures (surgical mortality) for some cancers may be significantly reduced if patients receive treatment in hospitals that perform large volumes of the surgical procedure annually.

Gemzar®/Taxol® Effective for Recurrent Bladder Cancer (2/12/2002)
According to recent results published in the journal Cancer, the chemotherapy combination consisting of Gemzar® and Taxol® appears effective for patients with advanced bladder cancer that has recurred following treatment with Platinol®-based chemotherapy.

Novel Agent Appears Promising for Solid Cancers (2/9/2002)
SCH66336, a novel ras inhibitor, appears promising in early phase clinical trials for the treatment of various cancers, as recently reported at the 92nd Annual Meeting of the American Association for Cancer Research.

Second-Opinion Pathology Discrepancies High for Bladder Cancer (2/5/2002)
Pathological diagnosis dictates treatment options for patients with bladder cancer. Pathological diagnosis is the cellular specificity of a biopsy specimen including the cell type, growth rate, aggressiveness and other biological characteristics of the cancer. Thus, correct initial diagnosis is imperative in order to correctly determine optimal treatment regimens for patients. However, results from a recent study published in the journal Cancer indicate that pathologic diagnosis may be incorrect in a significant number of bladder cancer specimens and second pathology opinions may be warranted.